Overview
To study the clinical application of 99mTc-H7ND SPECT/CT imaging in the efficacy evaluation and prediction of non-small cell lung cancer (NSCLC)
Description
This study was a prospective, controlled, single-center clinical study.
To evaluate the value of 99mTc-H7ND imaging in the evaluation of stable disease in patients with non-small cell lung cancer (NSCLC) assessed by RECIST1.1, and to predict the efficacy of subsequent treatment (second-line treatment).
Patients with NSCLC confirmed by cytology or pathology, who were unable to undergo radical surgery because of recurrence, metastasis, or their own conditions, and who had completed 2-4 cycles of first-line therapy and had RECIST1.1 assessment (SD) were divided into 2 groups:
Experimental group: 99mTc-H7ND SPECT/CT imaging performed Control group: 99mTc-H7ND SPECT/CT imaging was not performed
Eligibility
Inclusion Criteria:
- Patients aged from 18 to 80 years old;
- patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions;
- Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period;
- Patients had at least one measurable lesion;
- No local radiotherapy for primary or metastatic lesions within 28 days;
- ECOG score 0-2;
- Expected survival time ≥3 months;
- Voluntarily participate and sign informed consent.
Exclusion Criteria:
- Women who plan to become pregnant within 6 months, or are pregnant or lactating.
- Patients with severe brain or bone metastases;
- Severe anemia and severe liver and kidney damage;
- Pathological or long-term follow-up results may not be available;
- The relevant control imaging data and clinical data were not available;
- Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases);
- Received any surgery or invasive treatment or procedure within 4 weeks before enrollment;
- Cannot tolerate standard second-line therapy or other first-line therapies.
- Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies;
- Protocol imaging contraindications were present;
- The investigator considered it inappropriate to participate in the study.